Read + Share
Amedeo Smart
Independent Medical Education
Zhang F, Guo W, Zhou B, Wang S, et al. Research article: Three-year Follow-up of Neoadjuvant PD-1 inhibitor (Sintilimab) in Non-Small Cell Lung Cancer. J Thorac Oncol 2022 May 9. pii: S1556-0864(22)00216.PMID: 35550174
Email
LinkedIn
Facebook
Twitter
Privacy Policy